B+
Bull case
25%
Probability
Target price
$11.00
+39.9% vs current
LFST
Lifestance Health GroupBNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-11
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$9.75
+24.0% vs current
B-
Bear case
25%
Probability
Target price
$7.25
-7.8% vs current
AI sentiment snapshot
Latest data as of 2026-05-09
Recent news sentiment (30D)
-29.3
Negative
Company
-
Unavailable
Macro
-29.3
Negative
Pulse
-
Unavailable
Sentiment proxy
+56.0
Score
AI commentary
Tone improved after the May 7, 2026 earnings release because primary company materials showed a clear beat-and-raise and secondary coverage framed the print positively. However, this was a T+3 follow-up with sparse visible analyst revision evidence in the checked sources, and the peer set remains loose, so sentiment is better but still best treated as cautious monitoring rather than a fully validated rerating.
RankAlpha Sentiment Codex - 2026-05-09
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-07catalystQ1 beat-and-raise resets near-term expectationsHigh impact
LifeStance reported Q1 2026 revenue of $403.5M (+21% YoY), net income of $14.2M, adjusted EBITDA of $51.1M (+48% YoY), and raised FY2026 revenue, Center Margin, and adjusted EBITDA guidance; management cited higher visit volumes, improved clinician productivity, and higher revenue per visit as key drivers [#8-K-2026-05-07].
2026-08-07eventQ2 execution against raised guide becomes the next proof pointMedium impact
Company guidance now calls for Q2 2026 revenue of $405M-$425M and adjusted EBITDA of $50M-$60M, so the next setup is whether clinician growth, visit volume, and total revenue per visit sustain the post-print reset [#8-K-2026-05-07].
2027-05-09catalystBuyback plus cash generation can cushion downside if operations stay on trackMedium impact
The 10-Q says the board authorized a $100.0M repurchase program, the company repurchased 7.0M shares for about $49.1M in Q1, and about $50.9M remained as of March 31, 2026; the same filing also showed $33.1M of operating cash flow and debt covenant compliance, which supports a steadier capital-allocation backdrop [#10-Q-2026-05-07].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-09 • Updated nightlySource: Internal modelMethodology